We need urgent selleckbio steps to improve ethical quality of clinical research and harmonize local regulations with global guidelines. These steps would include: Creation of a central ethics and scientific review body to review and conclude whether the clinical trial meets the benchmarks of social value, scientific validity, fair subject selection and favorable benefit: risk ratio Development of clear regulatory guidance on institutional EC responsibilities, composition, quorum, functions and operations, with specific focus on protection of vulnerable subjects, and EC responsibility for oversight of conduct of clinical research by the investigator. Development of clear regulatory guidance on informed consent process, and documentation, with special emphasis on autonomy, capacity, and literacy.

Mandatory education and training of EC members in science, ethics and regulation of clinical research. Mandatory education and training of investigator and site staff members in science, ethics and regulation of clinical research. Accreditation of ethics committees and investigator sites. Regulatory inspections of investigator sites, ECs and sponsors. These actions are essential for creation of a robust ethical framework for clinical research, which could boost public confidence and provide assurance that the rights, safety and well-being of trial subjects are protected, in compliance with the global principles. Footnotes Source of Support: Nil Conflict of Interest: None declared.

Sir, This recent article (PICR January 2010;1:6-10) states conventionally that ??James Lind is considered thefirst physician to have conducted a controlled clinical trial of the modern era?? Unfortunately there is no evidence that Lind conducted the trial he claimed, nor were there any sailors with scurvy on the Salisbury on 20 May 1747.[1]

A total of 100 patients were consulted during the six-month study period, in an out-patient department at Rohini Superspeciality Hospital. Of these 100 prescriptions, 72% of the patients were in the age group of 65-67 years, followed by 26% in 68-70 years and 2% who were >70 years, and this was found to be higher in men 69% than in women 31%. The numbers of drugs prescribed were in the range of 4-6 per prescription. The Sociodemographic status such as Educational qualification, Occupation, Monthly Income, and Social habits of the patients was summarized in Table 1.

Hypertensive patients were classified on the basis of Joint National Committee (JNC-7) was summarized in Table 2. Table 1 Sociodemographic status of the Cilengitide patients Table 2 Classification of hypertensive patients on the basis selleckchem Pazopanib of JNC-7 The most common drug classes involved in the study was Calcium Channel Blockers 37% followed by Angiotensin II receptor antagonists 21%, and other prescribing patterns of Anti-Hypertensive Drug Monotherapy were summarized in Table 3.